How current Alzheimer's treatment failures are paving a new promising pathway
An Expert View from RJ Tesi, co-founder and chief executive of INmune Bio.
Alzheimer’s disease (AD) and related dementias are an enormous economic burden for taxpayers, patients, their families, medical systems, and society as a whole. To date, no truly efficacious drugs for AD have been developed; moreover, all new anti-AD drugs developed have failed. To succeed where previous drugs have failed in development, new approaches to treat AD are essential.
As an industry that has been stalled by groupthink, it is time to embrace new avenues in developing agents for cognitive and behavioral symptoms of AD combined with enhanced trial methods. The learnings from prior failures can help improve approaches to address the unmet needs of patients with AD for improved cognition and amelioration of neuropsychiatric symptoms.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze